Lassa Virus Replicon Particle Vaccine Protects Strain 13/N Guinea Pigs Against Challenge With Geographically and Genetically Diverse Viral Strains . (31st January 2022)

• Record Type: Journal Article
• Authors: Spengler, Jessica R; Kainulainen, Markus H; Welch, Stephen R; Coleman-McCray, JoAnn D; Harmon, Jessica R; Condrey, Jillian A; Scholte, Florine E M; Nichol, Stuart T; Montgomery, Joel M; Albariño, César G; Spiropoulou, Christina F
• Is Part Of: Journal of infectious diseases. Volume 226:Number 9(2022)
• Page Start: 1545
• Page End: 1550
• Publication Date: 2022-01-31
• Subjects: Lassa fever -- virus -- hemorrhagic fever -- strain 13/N guinea pigs -- animal model -- disease -- viral replicon particle -- vaccine -- protection; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiac028
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Lassa virus (LASV) causes mild to severe hemorrhagic fever disease in humans. Strain 13/N guinea pigs are highly susceptible to infection with LASV strain Josiah (clade IV), providing a critical model system for therapeutics and vaccine development. To develop additional models of disease, we detail the clinical course in guinea pigs infected with 5 geographically and genetically diverse LASV strains. Two of the developed models (LASV clades II and III) were then used to evaluate efficacy of a virus replicon particle vaccine against heterologous LASV challenge, demonstrating complete protection against clinical disease after a single vaccination dose.